# Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

> **NCT06126263** · — · UNKNOWN · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 1000 (estimated)

## Conditions studied

- Streptococcal Sepsis
- Invasive Group A Beta-Haemolytic Streptococcal Disease
- Necrotizing Soft Tissue Infection
- Infection, Bloodstream
- Infection, Bacterial
- Streptococcal Toxic Shock Syndrome

## Interventions

- **DRUG:** Linezolid
- **DRUG:** Clindamycin

## Key facts

- **NCT ID:** NCT06126263
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126263, "Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06126263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*